Michael Kramer

Michael Kramer

Michael Kramer is the Founder of Mott Capital Management. His unique investment philosophy centers on seeking investment opportunities that are influenced by everyday life activities, and by observing new trends and products that are popular or are trending towards popularity. Additionally, he devotes a significant part of his research to global macroeconomics and central bank policies impacting financial markets.

Kramer runs the Mott Capital Management actively managed long-only Thematic Growth Portfolio, which holds these stocks: AAPL, ACAD, ALKS, CELG, DEO, DIS, GOOGL, MA, MO, NFLX, NXPI, RTN, SWKS TSLA, UL, V, VOD and VZ.

Kramer began his career in high-risk trading environments, trading both US and international equities. His trading skills coupled with his comprehensive, financial analysis of public companies, have given him a unique perspective on investing, which stands out from analysts who simply look at top-line numbers. In addition to fundamental analysis, Kramer also incorporates technical and options market analysis into his research.

Kramer is a fundamental writer for Investopedia.com, analyzing stocks and market news that is helpful for everyday investors to make short and long-term investment decisions.

  • Showing 1216-1225 of 1,225 items
  • <<
  • ...
  • 80
  • 81
  • 82
  1. Stocks

    Analysts Weigh in on Sirius/Pandora (SIRI, P)

    Shares of Pandora are receiving a boost this morning after RBC and OPCO both saw the potential for Sirius and Pandora to ...
  2. Stocks

    Allergan Viewed Positively At JP Morgan (AGN)

    This morning AGN's rating and price target were reiterated at JP Morgan, which sees the stock a compelling opportunity.
  3. Stocks

    Lilly Shares Spike On Jardiance Approval (LLY)

    Shares of Eli Lilly & Co (LLY) are spiking after the FDA approved and expanded the label for Jardiance.
  4. Stocks

    Glaxo Files For COPD Drug In Europe (GSK, INVA)

    Glaxo and Innoviva are moving higher on the heels of positive news in both Europe and Japan for a COPD drug.
  5. Stocks

    Could Pandora Media Be Sold? (P, SIRI)

    News outlets reported this morning Pandora may be open to a sale to Sirius.
  6. Stocks

    Allergan Amgen File For ABP 215 (AGN, AMGN)

    Amgen and Allergan file in to get approval for Avastin biosimilar ABP 215 in Europe.
  7. Stocks

    RBC Sees Upside To Broadcom (AVGO)

    In a research noted this morning RBC said it believes Broadcom could beat its current estimates and increase its dividend.
  8. Stocks

    Is the Johnson & Johnson Bid for Actelion a Growth Play? (JNJ)

    Both Johnson & Johnson and Actelion have recently confirmed they are both in preliminary acquisition talks.
  9. Stocks

    Eli Lilly's Drug Solanezumab Failed In A Key Alzheimer's Disease Trial (LLY, BIIB)

    Eli Lilly & Co. reported that topline results for its phase III trial for Solanezumab, a monoclonal antibody, failed ...
  10. Stocks

    Merck Announces Dividend Increase, Offering Attractive Yield (MRK)

    On November 22nd, 2016 Merck announced it was increasing it dividend.
  • Showing 1216-1225 of 1,225 items
  • <<
  • ...
  • 80
  • 81
  • 82